101. A novel method for preparing Eligulstat through chiral resolution
- Author
-
Du Jianxun, Chu Weiming, Wenhua Feng, Chunying Ma, and Meng-Meng Zhang
- Subjects
Pyrrolidines ,Recrystallization (geology) ,First line ,Clinical Biochemistry ,Pharmaceutical Science ,01 natural sciences ,Biochemistry ,Structure-Activity Relationship ,Drug Discovery ,Enzyme Inhibitors ,Molecular Biology ,Gaucher Disease ,Dose-Response Relationship, Drug ,Molecular Structure ,010405 organic chemistry ,Chemistry ,Organic Chemistry ,Combinatorial chemistry ,Chiral resolution ,0104 chemical sciences ,010404 medicinal & biomolecular chemistry ,Glucosyltransferases ,Yield (chemistry) ,Reagent ,Molecular Medicine ,Racemic mixture ,Ceramide glucosyltransferase inhibitor ,Eliglustat - Abstract
Eliglustat is a ceramide glucosyltransferase inhibitor work as first line oral therapy for adults with Gaucher disease type 1 (a rare disease) at present. Although the eliglustat in enantiomerically pure forms is obtained by asymmetric syntheses, the reported methods suffer from many limits when it comes to industrial applications. Therefore, the preparation of a racemic mixture followed by resolution can still be a viable and straightforward alternative, especially when it could be adapted to large scale. Herein, we developed an effective and practical synthetic route to prepare stereoisomers mixture of eliglustat, and a novel chiral resolution method to prepare eliglustat. Using 1,1'-Binaphthyl-2,2'-diyl -hydrogenphosphate (BNDHP) as resolution reagent, optical pure eliglustat (e.e. >99%, 13.97% total yield) could be obtained after recrystallization.
- Published
- 2020
- Full Text
- View/download PDF